| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |